valproic acid has been researched along with Disorder, Borderline Personality in 20 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Excerpt | Relevance | Reference |
---|---|---|
" Participants were evaluated at baseline and after 12 weeks with: Clinical Global Impression - Severity (CGI-S), Hamilton Scales for depression and anxiety (HAM-D, HAM-A), Social and Occupational Functioning Assessment Scale (SOFAS), borderline personality disorder severity index (BPDSI), Barratt Impulsiveness Scale - version 11 (BIS-11), Modified Overt Aggression Scale (MOAS), Self-Harm Inventory (SHI) and Dosage Record Treatment Emergent Symptom Scale (DOTES)." | 6.79 | Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. ( Bellino, S; Bogetto, F; Bozzatello, P; Rocca, G, 2014) |
" The anticonvulsants valproate and topiramate appeared to have the most empirical support for having a favorable effect on symptoms of borderline personality disorder." | 4.85 | [Empirical evidence for the use of anticonvulsants in personality disorders]. ( Emrich, HM; Sieberer, M, 2009) |
" Participants were evaluated at baseline and after 12 weeks with: Clinical Global Impression - Severity (CGI-S), Hamilton Scales for depression and anxiety (HAM-D, HAM-A), Social and Occupational Functioning Assessment Scale (SOFAS), borderline personality disorder severity index (BPDSI), Barratt Impulsiveness Scale - version 11 (BIS-11), Modified Overt Aggression Scale (MOAS), Self-Harm Inventory (SHI) and Dosage Record Treatment Emergent Symptom Scale (DOTES)." | 2.79 | Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. ( Bellino, S; Bogetto, F; Bozzatello, P; Rocca, G, 2014) |
"Fifty-two outpatients with DSM-IV borderline personality disorder were randomly assigned to receive divalproex (N=20) or placebo (N=32), double-blind, for 12 weeks." | 2.71 | Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. ( Coccaro, EF; Hollander, E; Jiang, P; Smith, TB; Swann, AC, 2005) |
"Borderline personality disorder is characterized by affective instability, impulsivity, and aggression and is associated with considerable morbidity and mortality." | 2.70 | A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. ( Allen, A; Bienstock, CA; Grossman, R; Hollander, E; Lopez, RP; Merkatz, L; Siever, LJ; Stein, DJ, 2001) |
"Target symptoms in pharmacotherapy of borderline personality disorder include mood instability, anxiety, and impulsivity." | 2.68 | An open trial of valproate in borderline personality disorder. ( Frenkel, M; Hollander, E; Islam, MN; Simeon, D; Stein, DJ, 1995) |
"These findings support that divalproex ER is an efficacious and well-tolerated pharmacologic agent for BPD, with the additional advantage of single daily dosing at bedtime." | 1.34 | An open-label trial of divalproex extended-release in the treatment of borderline personality disorder. ( Baker, B; Braun, A; Chaplin, W; Hollander, E; Simeon, D, 2007) |
"In this study of patients with borderline personality disorder (BPD) or antisocial personality disorder (ASPD) hospitalized because of aggressive behavior, auditory and visual P300 evoked potentials were obtained prior to treatment with valproate." | 1.33 | Auditory and visual P300 evoked potentials do not predict response to valproate treatment of aggression in patients with borderline and antisocial personality disorders. ( Patrick, G; Reeves, RR; Struve, FA, 2005) |
"In this study of borderline and antisocial personality disorder patients hospitalized with aggressive behavior, EEGs were obtained prior to treatment with valproate." | 1.32 | EEG does not predict response to valproate treatment of aggression in patients with borderline and antisocial personality disorders. ( Patrick, G; Reeves, RR; Struve, FA, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (25.00) | 18.2507 |
2000's | 12 (60.00) | 29.6817 |
2010's | 3 (15.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bozzatello, P | 2 |
Rocca, P | 1 |
Bellino, S | 2 |
Rocca, G | 1 |
Bogetto, F | 1 |
Kawamura, S | 1 |
Sakai, A | 1 |
Endo, T | 1 |
Maruta, M | 1 |
Sieberer, M | 1 |
Emrich, HM | 1 |
Gescher, DM | 1 |
Malevani, J | 1 |
Moen, R | 1 |
Freitag, M | 1 |
Miller, M | 1 |
Lee, S | 1 |
Romine, A | 1 |
Song, S | 1 |
Adityanjee, A | 1 |
Schulz, SC | 1 |
Reeves, RR | 2 |
Struve, FA | 2 |
Patrick, G | 2 |
Zanarini, MC | 2 |
Hollander, E | 4 |
Swann, AC | 1 |
Coccaro, EF | 1 |
Jiang, P | 1 |
Smith, TB | 1 |
Simeon, D | 2 |
Baker, B | 1 |
Chaplin, W | 1 |
Braun, A | 1 |
Stein, DJ | 2 |
Frenkel, M | 1 |
Islam, MN | 1 |
Wilcox, J | 1 |
Wilcox, JA | 1 |
Prakash, R | 1 |
Roback, HB | 1 |
Hirschman, S | 1 |
Dolberg, OT | 1 |
Stern, L | 1 |
Grunhaus, LJ | 1 |
Fehr, C | 1 |
GrĂ¼nder, G | 1 |
Hiemke, C | 1 |
Dahmen, N | 1 |
Townsend, MH | 1 |
Cambre, KM | 1 |
Barbee, JG | 1 |
Allen, A | 1 |
Lopez, RP | 1 |
Bienstock, CA | 1 |
Grossman, R | 1 |
Siever, LJ | 1 |
Merkatz, L | 1 |
Frankenburg, FR | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.[NCT03418675] | Phase 2 | 80 participants (Actual) | Interventional | 2018-11-26 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
A clinician-administered assessment of anxiety that will be assessed at all study visits (Visit 1-Visit 8). Changes in scores from baseline to final visit will be assessed. Higher scores (up to 56) indicate higher levels of anxiety, with 0 being no symptoms of anxiety. (NCT03418675)
Timeframe: assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to Week 12) is reported
Intervention | change in score on a scale (Mean) |
---|---|
Placebo | -2.41 |
Rexulti | -4.88 |
A clinician-administered assessment of depression that will be assessed at all study visits (Visits 1-8). Higher total scores indicate higher levels of depression (up to 52), while a score of 0 would indicate no depressive symptoms. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported
Intervention | change in score on a scale (Mean) |
---|---|
Placebo | -2.09 |
Rexulti | -3.81 |
A self-report assessment of impulsivity that will be assessed at baseline and visit 8. The BIS is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Items are scored on a 4-point scale: (Rarely/Never = 1, Occasionally = 2, Often = 3, Almost Always/Always = 4). These scores are summed to produce an overall impulsivity score ranging from 30 (not impulsive) to 120 (extremely impulsive). (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)
Intervention | score on a scale (Mean) | |
---|---|---|
Visit 1 | Visit 8 | |
Placebo | 76.53 | 68.13 |
Rexulti | 72.27 | 70.5 |
A self rated scale used to measure severity and change. The first 12 items of the scale are on a scale from 1-5, with 5 meaning that the item caused extreme distress, severe difficulties in relationships, and/or kept them from getting things done. The lowest rating (1) means it caused little or no problems. Items 13-15 (positive behaviors) are rated according to frequency. Completed at every visit. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported
Intervention | score on a scale (Mean) | |
---|---|---|
Visit 1 | Visit 8 | |
Placebo | 40.90 | 29.15 |
Rexulti | 40.54 | 23.15 |
"A self-report scale measuring suicidality. Subjects will complete the scale at all visits. Subjects are asked about suicidal thoughts. If answers are no, rater can proceed to suicidal behavior section where subject is asked about any non-suicidal self injurious behavior. If yes, subject is asked about intensity of ideations. In the event of serious threat to themselves, the subject will be escorted to the emergency room. Total score indicates severity of suicidal ideation and behavior, with lower scores representing lower levels of suicidality and higher scores representing higher levels of suicidality. A score of 0 would reflect no suicidality present, whereas a maximum score of 5 would reflect active suicidal ideation with intent to act." (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)
Intervention | score on a scale (Mean) | |
---|---|---|
Visit 1 | Visit 8 | |
Placebo | 1.15 | 0.23 |
Rexulti | 0.73 | 0.08 |
A short-structured interview that assesses comorbid psychiatric disorders according to the DSM 5 criteria. This assessment will be done during the baseline visit. (NCT03418675)
Timeframe: Baseline (Week 1)
Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Major Depressive Episode (Current) | Major Depressive Episode (Past) | Manic Episode (Current) | Manic Episode (Past) | Hypomanic Episode (Current) | Bipolar I Disorder (Current) | Bipolar I Disorder (Past) | Bipolar II Disorder (Current) | Bipolar II Disorder (Past) | Panic Disorder (Current) | Panic Disorder (Lifetime) | Agoraphobia (Current) | Social Anxiety Disorder (Current) | Obsessive Compulsive Disorder (Current) | Post Traumatic Stress Disorder (Current) | Alcohol Use Disorder (Past 12 months) | Substance Use Disorder (Past 12 months) | Any Psychotic Disorder (Current) | Any Psychotic Disorder (Lifetime) | Major Depressive Disorder with Psychotic Features (Current) | Major Depressive Disorder with Psychotic Features (Past) | Anorexia Nervosa (current) | Bulimia Nervosa (Current) | Binge Eating Disorder (Current) | Generalized Anxiety Disorder (Current) | Antisocial Personality Disorder (Lifetime) | ADHD Combined Type (Current) | ADHD Inattentive Type (Current) | ADHD Hyperactive Type (Current) | Tourette's Syndrome (Lifetime) | Persistent Motor Tic Disorder (Lifetime) | Provisional Vocal Tic Disorder (Lifetime) | Provisional Tic Disorder (Lifetime) | Specific Phobia | Body Dysmorphic Disorder (Current) | |
Placebo | 16 | 12 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 6 | 11 | 7 | 6 | 3 | 9 | 13 | 11 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 10 | 8 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 4 | 3 |
Rexulti | 18 | 18 | 2 | 3 | 0 | 0 | 0 | 0 | 1 | 6 | 10 | 9 | 9 | 3 | 12 | 8 | 8 | 0 | 1 | 0 | 0 | 1 | 4 | 4 | 15 | 4 | 4 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 2 |
A self-report assessment of patient perceived quality of life that will be assessed at baseline and visit 8. Higher scores indicate a higher quality of life, whereas lower scores indicate a lower quality of life. Participants are asked to rate the importance of each domain on a 3-point scale ranging from 1=not important to 3=very important, and to rate how satisfied they are with that domain on a 6-point scale, ranging from -3=very dissatisfied to +3=very satisfied. In scoring, importance ratings are multiplied by satisfaction ratings to produce weighted satisfaction scores for each of the 16 domains. Weighted satisfaction scores are summed and divided by the number of domains that were rated as important or very important to produce a raw score, which is then converted to a t-score, which provides a proxy measurement for perceived quality of life. T-scores range from very low perceived quality of life (0-36) to high perceived quality of life (58-77). (NCT03418675)
Timeframe: Baseline (Week 1), Week 12 (Visit 8)
Intervention | score on a scale (Mean) | |
---|---|---|
Visit 1 | Visit 8 | |
Placebo | 28.89 | 30.75 |
Rexulti | 28.70 | 35.71 |
A self-report scale assessing Borderline Personality severity that will be assessed at all visits.This scale is assessing severity and change in BPD symptoms. This is a 9-item scale measuring severity of different aspects of Borderline Personality Disorder, with each item rated on a 0-4 scale, 0=no symptoms, 4=severe symptoms. Total scores range from 0-36. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
Intervention | score on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
Placebo | 18.2 | 12.8 | 10.7 | 10.7 | 9.7 | 9.6 | 8.7 | 9.3 |
Rexulti | 17.6 | 10.9 | 7.9 | 8.0 | 7.0 | 6.6 | 6.0 | 5.8 |
Subjects will complete the SDS at all visits. The change in scores from baseline to study completion will be assessed. The scale itself assesses the level of disability from borderline personality disorder (or target disorder) with higher scores indicating a more debilitating disorder. Scores range from 0-30. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
Intervention | score on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
Placebo | 17.3 | 13.3 | 11.5 | 12.4 | 11.7 | 11.2 | 12.0 | 12.7 |
Rexulti | 15.8 | 10.7 | 7.8 | 7.8 | 7.0 | 7.9 | 6.9 | 7.7 |
An instrument that helps evaluate a broad range of psychological problems and symptoms of Borderline Personality Disorder psychopathology. This will be assessed at baseline and visit 8.The 115 items are rated by using a 5-step Likert scale (0=not at all, 4=very strong) and provide a global picture of borderline psychopathology. Global scores of borderline psychopathology are calculated by summing 12 items and range from 0-48. Higher scores indicate more severe symptoms of Borderline Personality Disorder. (NCT03418675)
Timeframe: Baseline, Visit 8 (Week 12)
Intervention | score on a scale (Mean) | |
---|---|---|
Visit 1 | Visit 8 | |
Placebo | 26.17 | 20.25 |
Rexulti | 25.42 | 14.21 |
A clinician-administered scale assessing Borderline Personality Scale severity at all study visits. Scores range from 0-36. Higher scores represent worse Borderline Personality Disorder severity, and lower scores represent milder Borderline Personality Disorder severity. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
Intervention | score on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
Placebo | 14.9 | 7.6 | 4.7 | 6 | 4.2 | 5.7 | 5 | 8.4 |
Rexulti | 14.9 | 6.7 | 5.3 | 4.4 | 4.5 | 4.9 | 4 | 3.1 |
4 reviews available for valproic acid and Disorder, Borderline Personality
Article | Year |
---|---|
[Empirical evidence for the use of anticonvulsants in personality disorders].
Topics: Amines; Anticonvulsants; Borderline Personality Disorder; Carbamazepine; Cyclohexanecarboxylic Acids | 2009 |
[Mood stabilizer in the psychopharmacotherapy of borderline personality disorder].
Topics: Anticonvulsants; Antimanic Agents; Borderline Personality Disorder; Carbamazepine; Female; Fructose; | 2009 |
Update on pharmacotherapy of borderline personality disorder.
Topics: Affect; Antimanic Agents; Antipsychotic Agents; Borderline Personality Disorder; Humans; Placebos; R | 2004 |
[The use of valproic acid in the treatment of borderline personality disorder].
Topics: Antimanic Agents; Borderline Personality Disorder; Humans; Valproic Acid | 1997 |
7 trials available for valproic acid and Disorder, Borderline Personality
Article | Year |
---|---|
Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid.
Topics: Adult; Antimanic Agents; Borderline Personality Disorder; Drug Therapy, Combination; Fatty Acids, Om | 2014 |
Efficacy of extended-release divalproex combined with "condensed" dialectical behavior therapy for individuals with borderline personality disorder.
Topics: Adult; Antimanic Agents; Behavior Therapy; Borderline Personality Disorder; Checklist; Combined Moda | 2012 |
Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder.
Topics: Adult; Age of Onset; Aggression; Anticonvulsants; Borderline Personality Disorder; Double-Blind Meth | 2005 |
An open trial of valproate in borderline personality disorder.
Topics: Adult; Ambulatory Care; Borderline Personality Disorder; Drug Administration Schedule; Female; Human | 1995 |
Divalproex sodium in the treatment of aggressive behavior.
Topics: Adult; Aggression; Bipolar Disorder; Borderline Personality Disorder; Case-Control Studies; Female; | 1994 |
A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.
Topics: Adolescent; Adult; Aggression; Ambulatory Care; Anticonvulsants; Borderline Personality Disorder; Co | 2001 |
Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.
Topics: Adult; Aggression; Anger; Anticonvulsants; Bipolar Disorder; Borderline Personality Disorder; Comorb | 2002 |
9 other studies available for valproic acid and Disorder, Borderline Personality
Article | Year |
---|---|
Combination of Omega-3 Fatty Acids and Valproic Acid in Treatment of Borderline Personality Disorder: A Follow-Up Study.
Topics: Adult; Borderline Personality Disorder; Controlled Clinical Trials as Topic; Docosahexaenoic Acids; | 2018 |
Atypical depression as a premonitory symptom of migraine managed by an oral contraceptive.
Topics: Adult; Alprazolam; Borderline Personality Disorder; Calcium Channel Blockers; Contraceptives, Oral, | 2008 |
EEG does not predict response to valproate treatment of aggression in patients with borderline and antisocial personality disorders.
Topics: Adult; Aggression; Anticonvulsants; Antisocial Personality Disorder; Borderline Personality Disorder | 2003 |
Auditory and visual P300 evoked potentials do not predict response to valproate treatment of aggression in patients with borderline and antisocial personality disorders.
Topics: Adult; Aggression; Anticonvulsants; Antisocial Personality Disorder; Borderline Personality Disorder | 2005 |
An open-label trial of divalproex extended-release in the treatment of borderline personality disorder.
Topics: Adult; Aggression; Anticonvulsants; Borderline Personality Disorder; Delayed-Action Preparations; Fe | 2007 |
Divalproex sodium as a treatment for borderline personality disorder.
Topics: Adolescent; Adult; Anticonvulsants; Antimanic Agents; Arousal; Borderline Personality Disorder; Dose | 1995 |
Borderline personality and bipolar disorder.
Topics: Bipolar Disorder; Borderline Personality Disorder; Diagnosis, Differential; Humans; Psychotherapy; T | 1997 |
Increase in serum clomipramine concentrations caused by valproate.
Topics: Borderline Personality Disorder; Clomipramine; Drug Interactions; Female; Humans; Middle Aged; Selec | 2000 |
Treatment of borderline personality disorder with mood instability with divalproex sodium: series of ten cases.
Topics: Adult; Antimanic Agents; Borderline Personality Disorder; Female; Humans; Male; Middle Aged; Mood Di | 2001 |